Human Immunodeficiency Virus Type 1 RNA Levels in Rectal and Seminal Compartments After Switching to Long-Acting Cabotegravir Plus Rilpivirine: A Longitudinal Study

Human immunodeficiency virus type 1 RNA levels were longitudinally evaluated in 211 rectal and 152 seminal samples from 12 virologically suppressed participants switching to monthly long-acting cabotegravir plus rilpivirine or continuing with daily dolutegravir-abacavir-lamivudine. Maintenance of vi...

Full description

Saved in:
Bibliographic Details
Published inClinical infectious diseases Vol. 76; no. 3; pp. e748 - e751
Main Authors Masiá, Mar, Fernández-González, Marta, Agulló, Vanesa, Mascarell, Paula, Padilla, Sergio, García-Abellán, Javier, Gutiérrez, Félix
Format Journal Article
LanguageEnglish
Published United States 08.02.2023
Subjects
Anti-HIV Agents - therapeutic use
Anti-Retroviral Agents - therapeutic use
HIV Infections - drug therapy
HIV-1 - genetics
Humans
Longitudinal Studies
Rilpivirine - therapeutic use
RNA - therapeutic use
semen
long-acting antiretroviral therapy
rectal secretions
cabotegravir
rilpivirine
Online AccessGet full text

Cover

More Information
Summary:Human immunodeficiency virus type 1 RNA levels were longitudinally evaluated in 211 rectal and 152 seminal samples from 12 virologically suppressed participants switching to monthly long-acting cabotegravir plus rilpivirine or continuing with daily dolutegravir-abacavir-lamivudine. Maintenance of viral suppression in rectal and seminal compartments was comparable, and blips occurred with similar frequency with both treatment regimens. NCT02938520.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciac676